title: Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.
authors.forename: L F
authors.initials: LF
authors.lastname: Porrata
authors.forename: K
authors.initials: K
authors.lastname: Ristow
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: N
authors.initials: N
authors.lastname: Tuinistra
authors.forename: T M
authors.initials: TM
authors.lastname: Habermann
authors.forename: D J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: S M
authors.initials: SM
authors.lastname: Ansell
authors.forename: I N
authors.initials: IN
authors.lastname: Micallef
authors.forename: P B
authors.initials: PB
authors.lastname: Johnston
authors.forename: S N
authors.initials: SN
authors.lastname: Markovic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018655:Lymphocyte Count; D008224:Lymphoma, Follicular / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016499:Radioimmunotherapy; D012008:Recurrence; D000069283:Rituximab; D016879:Salvage Therapy; D016019:Survival Analysis; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan